Clinical Cancer Research, Vol 3, Issue 6 963-972, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis

R Uslu, N Borsellino, P Frost, H Garban, CP Ng, Y Mizutani, A Belldegrun and B Bonavida
Department of Microbiology, Jonsson Comprehensive Cancer Center, UCLA School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA.

Androgen ablation has been an effective treatment in patients with advanced prostate cancer. However, most treated patients develop hormonally resistant disease and do not respond to conventional chemotherapy. Immunotherapy against prostate cancer is an alternative approach in overcoming hormonal/drug-resistant prostate cancer. Cytotoxic immune lymphocytes kill target cells via the perforin/granzyme and the Fas-ligand (Fas-L) pathways. We hypothesize that tumor cells respond poorly to immunotherapy by developing resistance to killing by the Fas-L mechanism. This study investigated whether prostate tumor cells are sensitive to Fas-mediated killing. The human prostate carcinoma cell lines DU145, PC-3, and LnCAP were examined for their sensitivity to killing and apoptosis by the Fas-L agonist anti-Fas antibody and CTLs. All three lines moderately expressed the Fas antigen on the cell surface; however, all three lines were relatively resistant to cytotoxicity mediated by anti-Fas (CH-11) antibody. Pretreatment of DU145 and PC-3 with subtoxic concentrations of drugs followed by anti-Fas antibody resulted in synergistic cytotoxicity and apoptosis, whereas only an additive effect was obtained with LnCAP. Chemosensitization with drugs and anti-Fas was completely blocked by the addition of neutralizing anti-Fas antibody. The murine CTL hybridoma, PMMI, which kills only via the Fas-L pathway, was able to kill chemosensitized PC-3 and DU145 but not LnCAP cells. Furthermore, this cytotoxicity was blocked by anti-Fas neutralizing antibody. Chemosensitization of PC-3 and DU145 prostate tumor cells was not due to up-regulation of Fas-receptor antigen expression. Treatment of tumor cells with cisplatin did not down-regulate the antiapoptotic genes bcl-2, FAP-1, and c-myc. Further, there was no induction by cisplatin of Fas-L on the tumor cells, thus ruling out Fas/Fas-L-mediated autologous killing. These findings demonstrate that pretreatment of drug-resistant/CTL-resistant prostate DU145 and PC-3 tumor cells with subtoxic concentrations of certain chemotherapeutic drugs sensitizes the tumor cells to Fas-mediated cytotoxicity. These findings suggest that chemosensitization of tumor cells should optimize the response to immunotherapeutic interventions in the treatment of hormone-resistant/drug-resistant prostate cancer.

This article has been cited by other articles:

				J. Bertram, J. W. Peacock, C. Tan, A. L-F. Mui, S. W. Chung, M. E. Gleave, S. Dedhar, M. E. Cox, and C. J. Ong Inhibition of the Phosphatidylinositol 3'-Kinase Pathway Promotes Autocrine Fas-Induced Death of Phosphatase and Tensin Homologue-Deficient Prostate Cancer Cells. Cancer Res., May 1, 2006; 66(9): 4781 - 4788. [Abstract] [Full Text] [PDF]

				J. B. Garrison and N. Kyprianou Doxazosin Induces Apoptosis of Benign and Malignant Prostate Cells via a Death Receptor-Mediated Pathway Cancer Res., January 1, 2006; 66(1): 464 - 472. [Abstract] [Full Text] [PDF]

				H. Nakanishi, Y. Mizutani, A. Kawauchi, O. Ukimura, T. Shiraishi, M. Hatano, M. Mizuno, J. Yoshida, and T. Miki Significant Antitumoral Activity of Cationic Multilamellar Liposomes Containing Human IFN-{beta} Gene against Human Renal Cell Carcinoma Clin. Cancer Res., March 1, 2003; 9(3): 1129 - 1135. [Abstract] [Full Text] [PDF]

				J. G. Crowston, L. H. Chang, P. H. Constable, J. T. Daniels, A. N. Akbar, and P. T. Khaw Apoptosis Gene Expression and Death Receptor Signaling in Mitomycin-C-Treated Human Tenon Capsule Fibroblasts Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 692 - 699. [Abstract] [Full Text] [PDF]

				I. Meinhold-Heerlein, F. Stenner-Liewen, H. Liewen, S. Kitada, M. Krajewska, S. Krajewski, J. M. Zapata, A. Monks, D. A. Scudiero, T. Bauknecht, et al. Expression and Potential Role of Fas-Associated Phosphatase-1 in Ovarian Cancer Am. J. Pathol., April 1, 2001; 158(4): 1335 - 1344. [Abstract] [Full Text] [PDF]

				P. J. Frost, L. H. Butterfield, V. B. Dissette, J. S. Economou, and B. Bonavida Immunosensitization of Melanoma Tumor Cells to Non-MHC Fas-Mediated Killing by MART-1-Specific CTL Cultures J. Immunol., March 1, 2001; 166(5): 3564 - 3573. [Abstract] [Full Text] [PDF]

				R. Uslu, U. A. Sanli, C. Sezgin, B. Karabulut, E. Terzioglu, S. B. Omay, and E. Goker Arsenic Trioxide-mediated Cytotoxicity and Apoptosis in Prostate and Ovarian Carcinoma Cell Lines Clin. Cancer Res., December 1, 2000; 6(12): 4957 - 4964. [Abstract] [Full Text]

				A. Nesterov, X. Lu, M. Johnson, G. J. Miller, Y. Ivashchenko, and A. S. Kraft Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCaP from TRAIL-induced Apoptosis J. Biol. Chem., March 30, 2001; 276(14): 10767 - 10774. [Abstract] [Full Text] [PDF]